ClinicalTrials.gg
Not yet recruitingNCT07474714Updated Mar 17, 2026

Hyaluronic Acid Injection in Idiopathic Carpal Tunnel Syndrome; is it Effective as Local Corticosteroids

A Phase 3 interventional study of Low Molecular Weight Hyaluronic Acid and corticosteroid in Carpal Tunnel Syndrome (CTS), sponsored by Minia University Hospital. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Minia University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Carpal Tunnel Syndrome with a site in Egypt — 20 open to participants now, 22 under way, 1 of them phase 3. Carpal Tunnel Syndrome · Egypt.

Planned enrollment
21st of 53
60 · median 60
Started
2026
with 5 others
Phase 3
Only one
of the 64
Primary completion
2026-08
later than 17 of 21 live
Registered
57th of 64
by date

Among the 64 studies in Carpal Tunnel Syndrome with a site in Egypt, this one is the 21st largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2026, is the only one in phase 3, reaches primary completion later than 17 of the 21 other live ones, and was the 57th registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

20 of the 64 studies in Carpal Tunnel Syndrome with a site in Egypt are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Carpal Tunnel Syndrome with a site in Egypt, or all of them as a file.
02

Study summary

This study compares the effectiveness of two types of local injections-Hyaluronic Acid (HA) and corticosteroids-for treating mild to moderate idiopathic Carpal Tunnel Syndrome (CTS). Sixty adult patients will be assigned to receive one of the two injections under ultrasound guidance. The goal is to see if HA is as effective as the standard corticosteroid treatment in improving symptoms and nerve function over a 3-month follow-up period.

Read the detailed description

This is a prospective comparative 3-month follow-up study. Sixty adult patients diagnosed with mild or moderate idiopathic CTS by electro-diagnostic studies will be recruited from the Rheumatology and rehabilitation clinic at Minia University Hospitals, Egypt. Participants will be divided into two groups of 30: one receiving low molecular weight hyaluronic acid and the other receiving corticosteroids, both administered via ultrasound-guided perineural injection. Baseline and follow-up assessments at 1- and 3-months post-injection will include the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) scores, electro-diagnostic parameters (sensory and motor latencies, CMAP, etc.), and neuromuscular ultrasound examination (median nerve cross-sectional area, flattening ratio, etc.).

03

Conditions studied

  • Carpal Tunnel Syndrome (CTS)

Keywords

  • Carpal Tunnel Syndrome (CTS)
  • Hyaluronic Acid
  • Corticosteroid Injection
  • Ultrasound-Guided Injection
  • Median Nerve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Numbness or pain in the Median Nerve (MN) distribution.
  2. Nerve conduction studies (NCS) consistent with CTS as per the AANEM guidelines.
  3. An MN cross-sectional area (CSA) at the wrist >12 mm²

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe symptoms (indication for surgery).
  2. Patients who show improvement on medical treatment.
  3. Patients with previous surgical or injectional CTS treatment.
  4. Coexistence of brachial plexopathy, or thoracic outlet syndrome.
  5. Patients with infection at the site of injection.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Hyaluronic Acid Group

    Arm Description 30 adult patients with mild to moderate idiopathic CTS receiving ultrasound-guided perineural injection of low molecular weight Hyaluronic Acid.

    Drug: Low Molecular Weight Hyaluronic Acid

  • Active comparator
    Corticosteroid Group

    Arm Description 30 adult patients with mild to moderate idiopathic CTS receiving ultrasound-guided perineural injection of corticosteroids.

    Drug: corticosteroid

Interventions

  • DrugLow Molecular Weight Hyaluronic Acid

    Ultrasound-guided perineural injection of low molecular weight Hyaluronic Acid.

  • Drugcorticosteroid

    Ultrasound-guided perineural injection of corticosteroids

06

What researchers measure

Primary outcomes

  1. Change in Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) Scores

    Comparison of the BCTQ scores (symptom severity and functional status) between the Hyaluronic Acid and Corticosteroid groups.

    Time frame: Baseline, 1 month, and 3 months post-injection

  2. Change in Electro-diagnostic Parameters

    Comparison of sensory and motor electrodiagnostic parameters between the two groups, including peak sensory latency (ms), sensory nerve action potential - SNAP (µV), sensory conduction velocity - SCV (m/s), distal motor latency (ms), compound muscle action potential - CMAP (mV), and motor conduction velocity - MCV (m/s).

    Time frame: Time Frame Baseline, 1 month, and 3 months post-injection

  3. Change in Neuromuscular Ultrasound Examination Parameters

    Comparison of neuromuscular ultrasound parameters between the two groups, including the median nerve cross-sectional area (CSA) measured in mm², fascicular pattern, flattening ratio, and mobility of the median nerve.

    Time frame: Baseline, 1 month, and 3 months post-injection

07

Study locations

1 site
  • Minia University Hosopital
    Minya, 61111, Egypt
    • Facility of Medicine Minia University · Contactdean.med@mu.edu.eg · +20862342584
    • Yara Assem, MD · Sub investigator
    • Haidy Mohamed Osman, MD · Principal investigator
    • Fatma Ali, Prof · Principal investigator
08

References and documents

Publications

  • Senna MK, Shaat RM, Ali AAA. Platelet-rich plasma in treatment of patients with idiopathic carpal tunnel syndrome. Clin Rheumatol. 2019 Dec;38(12):3643-3654. doi: 10.1007/s10067-019-04719-7. Epub 2019 Aug 16. PubMed 31420812 ↗
  • Jiang J, Xing F, Luo R, Liu M. Effectiveness of Platelet-Rich Plasma for Patients With Carpal Tunnel Syndrome: A Systematic Review and meta-Analysis of Current Evidence in Randomized Controlled Trials. Front Pharmacol. 2022 Apr 27;13:834213. doi: 10.3389/fphar.2022.834213. eCollection 2022. PubMed 35571114 ↗
  • Malahias MA, Nikolaou VS, Johnson EO, Kaseta MK, Kazas ST, Babis GC. Platelet-rich plasma ultrasound-guided injection in the treatment of carpal tunnel syndrome: A placebo-controlled clinical study. J Tissue Eng Regen Med. 2018 Mar;12(3):e1480-e1488. doi: 10.1002/term.2566. Epub 2017 Dec 17. PubMed 28873284 ↗
  • Cansever U, Koldas Dogan S, Erdem Toslak I, Bilgilisoy Filiz M, Toraman NF. Comparison of the effectiveness of platelet-rich plasma (PRP) injection and steroid injection in patients with bilateral moderate carpal tunnel syndrome: a prospective randomized controlled trial. Injury. 2026 Mar;57(3):113018. doi: 10.1016/j.injury.2026.113018. Epub 2026 Jan 9. PubMed 41548406 ↗
  • Hong P, Zheng Y, Rai S, Ding Y, Zhou Y, Liu R, Li J. Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments. Front Pharmacol. 2022 Nov 10;13:906075. doi: 10.3389/fphar.2022.906075. eCollection 2022. PubMed 36438824 ↗
  • Buntragulpoontawee M, Chang KV, Vitoonpong T, Pornjaksawan S, Kitisak K, Saokaew S, Kanchanasurakit S. The Effectiveness and Safety of Commonly Used Injectates for Ultrasound-Guided Hydrodissection Treatment of Peripheral Nerve Entrapment Syndromes: A Systematic Review. Front Pharmacol. 2021 Mar 5;11:621150. doi: 10.3389/fphar.2020.621150. eCollection 2020. PubMed 33746745 ↗
  • Senlikci HB, Afsar SI, Cosar SN, Kurtcebe AN, Ozen S, Yemisci OU. The effectiveness of single-dose blinded platelet-rich plasma (PRP) vs. corticosteroid injection in mild-to-moderate carpal tunnel syndrome: A prospective, randomized, double blind study. J Bodyw Mov Ther. 2025 Jun;42:995-1001. doi: 10.1016/j.jbmt.2025.01.057. Epub 2025 Jan 31. PubMed 40325784 ↗
  • Lin CP, Chang KV, Huang YK, Wu WT, Ozcakar L. Regenerative Injections Including 5% Dextrose and Platelet-Rich Plasma for the Treatment of Carpal Tunnel Syndrome: A Systematic Review and Network Meta-Analysis. Pharmaceuticals (Basel). 2020 Mar 18;13(3):49. doi: 10.3390/ph13030049. PubMed 32197544 ↗
  • Wu YT, Ke MJ, Ho TY, Li TY, Shen YP, Chen LC. Randomized double-blinded clinical trial of 5% dextrose versus triamcinolone injection for carpal tunnel syndrome patients. Ann Neurol. 2018 Oct;84(4):601-610. doi: 10.1002/ana.25332. Epub 2018 Oct 4. PubMed 30187524 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Aug 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 16, 2026
StartEst.
Feb 2026
Primary completionEst.
Aug 2026
CompletionEst.
Sep 2026
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07474714
Lead sponsor
Minia University Hospital
Responsible party
Yara Assem (Lecturer of Rheumatology, Rehabilitation and Physical medicine, Minia University Hospital) — Principal investigator
First posted
Mar 16, 2026
Start date
Feb 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Mar 17, 2026

Study contacts

Yara Assem Assem, MD
Contact
yara.asem@mu.edu.eg
+201093383306
Haidy Mohamed Osman, Osman
Contact
haidy.muhamad@mu.edu.eg
+201097238632

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion